19 results on '"Karampatsas K"'
Search Results
2. Gastrointestinal, vaginal, nasopharyngeal, and breast milk microbiota profiles and breast milk metabolomic changes in Gambian infants over the first two months of lactation: A prospective cohort study
- Author
-
Karampatsas, K, Faal, A, Jaiteh, M, Garcia-Perez, I, Aller, S, Shaw, AG, Kopytek, A, Witney, AA, Le Doare, K, and The Imperial College Wellcome Trust Centre for Global Health Research
- Subjects
Milk, Human ,Bacteria ,Microbiota ,Infant, Newborn ,Infant ,1103 Clinical Sciences ,General Medicine ,Arthritis & Rheumatology ,Breast Feeding ,RNA, Ribosomal, 16S ,Humans ,Lactation ,Female ,Gambia ,Prospective Studies - Abstract
Background Microbiota composition in breast milk affects intestinal and respiratory microbiota colonization and the mucosal immune system's development in infants. The metabolomic content of breast milk is thought to interact with the microbiota and may influence developing infant immunity.\ud \ud Methods 107 Gambian mothers and their healthy, vaginally delivered, exclusively breastfed infants were included in our study. We analyzed 32 breast milk samples, 51 maternal rectovaginal swabs and 30 infants' rectal swabs at birth. We also analyzed 9 breast milk samples and 18 infants' nasopharyngeal swabs 60 days post-delivery. We used 16S rRNA gene sequencing to determine the microbiota composition. Metabolomic profiling analysis was performed on colostrum and mature breast milk samples using a multiplatform approach combining 1-H Nuclear Magnetic Resonance Spectroscopy and Gas Chromatography-Mass Spectrometry. \ud \ud Results Bacterial communities were distinct in composition and diversity across different sample types. Breast milk composition changed over the first 60 days of lactation. α-1,4- and α-1,3-fucosylated human milk oligosaccharides, and other 33 key metabolites in breast milk (monosaccharides, sugar alcohols and fatty acids) increased between birth and day 60 of life.\ud \ud Conclusions This study's results indicate that infant gut and respiratory microbiota are unique bacterial communities, distinct from maternal gut and breast milk, respectively. Breast milk microbiota composition and metabolomic profile change throughout lactation. These changes may contribute to the infant's immunological, metabolic, and neurological development and could consist the basis for future interventions to correct disrupted early life microbial\ud colonization.
- Published
- 2022
3. Chronic meningitis with intracranial hypertension and bilateral neuroretinitis following Mycoplasma pneumoniae infection
- Author
-
Karampatsas, K., primary, Patel, H., additional, Basheer, S. N., additional, and Prendergast, A. J., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Persistent Left Superior Vena Cava: A Problem in the Transvenous Pacing of the Heart
- Author
-
DOSIOS, T., primary, GORGOGIANNIS, D., additional, SAKORAFAS, G., additional, and KARAMPATSAS, K., additional
- Published
- 1991
- Full Text
- View/download PDF
5. Vaccine value profile for Klebsiella pneumoniae.
- Author
-
Dangor Z, Benson N, Berkley JA, Bielicki J, Bijsma MW, Broad J, Buurman ET, Cross A, Duffy EM, Holt KE, Iroh Tam PY, Jit M, Karampatsas K, Katwere M, Kwatra G, Laxminarayan R, Le Doare K, Mboizi R, Micoli F, Moore CE, Nakabembe E, Naylor NR, O'Brien S, Olwagen C, Reddy D, Rodrigues C, Rosen DA, Sadarangani M, Srikantiah P, Tennant SM, Hasso-Agopsowicz M, and Madhi SA
- Subjects
- Adult, Female, Humans, Infant, Pregnancy, Anti-Bacterial Agents therapeutic use, Drug Resistance, Multiple, Bacterial, Vaccination methods, Bacterial Vaccines immunology, Bacterial Vaccines administration & dosage, Klebsiella Infections prevention & control, Klebsiella Infections epidemiology, Klebsiella pneumoniae immunology, Klebsiella pneumoniae pathogenicity, Klebsiella pneumoniae drug effects
- Abstract
Klebsiella pneumoniae causes community- and healthcare-associated infections in children and adults. Globally in 2019, an estimated 1.27 million (95% Uncertainty Interval [UI]: 0.91-1.71) and 4.95 million (95% UI: 3.62-6.57) deaths were attributed to and associated with bacterial antimicrobial resistance (AMR), respectively. K. pneumoniae was the second leading pathogen in deaths attributed to AMR resistant bacteria. Furthermore, the rise of antimicrobial resistance in both community- and hospital-acquired infections is a concern for neonates and infants who are at high risk for invasive bacterial disease. There is a limited antibiotic pipeline for new antibiotics to treat multidrug resistant infections, and vaccines targeted against K. pneumoniae are considered to be of priority by the World Health Organization. Vaccination of pregnant women against K. pneumoniae could reduce the risk of invasive K.pneumoniae disease in their young offspring. In addition, vulnerable children, adolescents and adult populations at risk of K. pneumoniae disease with underlying diseases such as immunosuppression from underlying hematologic malignancy, chemotherapy, patients undergoing abdominal and/or urinary surgical procedures, or prolonged intensive care management are also potential target groups for a K. pneumoniae vaccine. A 'Vaccine Value Profile' (VVP) for K.pneumoniae, which contemplates vaccination of pregnant women to protect their babies from birth through to at least three months of age and other high-risk populations, provides a high-level, holistic assessment of the available information to inform the potential public health, economic and societal value of a pipeline of K. pneumoniae vaccines and other preventatives and therapeutics. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public-private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the WHO. All contributors have extensive expertise on various elements of the K.pneumoniae VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ziyaad Dangor reports financial support was provided by Bill & Melinda Gates Foundation. Ziyaad Dangor reports financial support was provided by World Health Organization. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. GBS vaccines in the UK: a round table discussion.
- Author
-
Thorn N, Guy RL, Karampatsas K, Powell M, Walker KF, Plumb J, Khalil A, Greening V, Eccleston E, Trotter C, Andrews N, Rush L, Sharkey C, Wallis L, Heath P, and Le Doare K
- Subjects
- Humans, United Kingdom epidemiology, Female, Streptococcal Vaccines therapeutic use, Streptococcal Vaccines immunology, Streptococcal Infections prevention & control, Streptococcal Infections epidemiology, Streptococcus agalactiae immunology
- Abstract
Background: Group B streptococcus (GBS) remains a leading cause of infant sepsis, meningitis and death despite intrapartum antibiotic prophylaxis. A vaccine is urgently required, and two candidates are in advanced clinical trials. For successful GBS vaccine implementation, especially if a vaccine is licensed based on an immunological threshold, there must be cross-sector engagement, effective advocacy, robust plans for phase IV studies and equitable access., Meeting: A round-table discussion, held at St George's University of London, reviewed the current position of GBS vaccines in the UK context, focusing on phase IV plans, convening a diverse group of stakeholders from across the UK, with a role in GBS vaccine licensure, advocacy, implementation or effectiveness evaluation.Presentations outlined the latest UK epidemiology, noting the rising infant invasive GBS (iGBS) infection rates from 1996 to 2021 for both early and late onset disease, with the highest disease rates in Black infants (1.1/1000 livebirths vs white infants (0.81/1000 livebirths). Potential coverage of the candidate vaccines was high (>95%). Regulatory input suggested that EU regulators would consider waiving the need for a pre-licensure efficacy study if a putative correlate of protection could be adequately justified. Phase IV study methodologies for a GBS vaccine were considered, largely based on previous UK maternal vaccine assessments, such as a nationwide cohort study design using a vaccine register and a maternal services dataset. Other strategies were also discussed such as a cluster or stepped-wedge randomised trial to evaluate implementation outcomes. Opportunities for advocacy, education and engagement with additional key partners were discussed and identified., Conclusions: With an approved GBS vaccine a near possibility, planning of phase IV studies and identification of critical barriers to implementation are urgently needed. Cross-sector engagement is essential and will facilitate a successful pathway., Competing Interests: No competing interests were disclosed., (Copyright: © 2024 Thorn N et al.)
- Published
- 2024
- Full Text
- View/download PDF
7. Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study.
- Author
-
Karampatsas K, Hall T, Voysey M, Carreras-Abad C, Cochet M, Ramkhelawon L, Peregrine E, Andrews N, Heath PT, and Le Doare K
- Subjects
- Humans, Infant, Female, Infant, Newborn, Male, United Kingdom, Fetal Blood immunology, Cohort Studies, Pregnancy, Adult, Serogroup, Immunity, Maternally-Acquired, Antibodies, Bacterial blood, Antibodies, Bacterial immunology, Streptococcus agalactiae immunology, Immunoglobulin G blood, Streptococcal Infections immunology
- Abstract
Introduction: Capsular polysaccharide (CPS) serotype-specific Immunoglobulin G (IgG) in cord blood has been proposed as a correlate of protection against invasive Group B Streptococcus (iGBS) disease. Although protective levels are required in infants throughout the window of vulnerability up to 3 months of age, little is known regarding the kinetics of GBS-specific IgG over this period., Methods: We enrolled 33 healthy infants born to mothers colonized with GBS. We collected cord blood and infant blood samples either at one (21-35 days), two (49-63 days), or three months of age (77-91 days). We measured GBS serotype-specific CPS IgG concentrations and calculated the decay rate using a mixed-effects model. We further explored whether the antibody kinetics were affected by common maternal and infant factors and estimated the correlation between IgG concentration at birth and one, two, and three months of age., Results: The half-life estimate of IgG concentration for homologous and non-homologous GBS serotypes in paired samples with detectable IgG levels at both time points was 27.4 (95 % CI: 23.5-32.9) days. The decay rate did not vary by maternal age (p = 0.7), ethnicity (p = 0.1), gravida (p = 0.1), gestation (p = 0.7), and infant sex (p = 0.1). Predicted IgG titres above the assay lower limit of quantification on day 30 strongly correlated with titres at birth (Spearman correlation coefficient 0.71 [95 % CI: 0.60-0.80])., Conclusion: Our results provide a basis for future investigations into the use of antibody kinetics in defining a serocorrelate of protection against late-onset iGBS disease., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Paul Heath reports financial support was provided by National Institute for Health Research. MV is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca. PTH has conducted studies on behalf of St George’s University of London funded by GBS vaccine manufacturers, including Minervax and Pfizer, but receives no personal funding for these activities. KLD is supported by Future Leaders Fellowships by UK Research and Innovation Future Leaders Fellowship (MR/S016570/1) and has conducted studies on behalf of St George’s University of London funded by GBS vaccine manufacturers, including Minervax and Pfizer, but receives no personal funding for these activities. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.]., (Copyright © 2024 The Authors. Published by Elsevier India Pvt Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.
- Author
-
Davies HG, Thorley EV, Al-Bahadili R, Sutton N, Burt J, Hookham L, Karampatsas K, Lambach P, Muñoz F, Cutland CL, Omer S, and Le Doare K
- Abstract
Introduction: The GAIA (Global Alignment on Immunisation Safety Assessment in Pregnancy) consortium was established in 2014 with the aim of creating a standardised, globally coordinated approach to monitoring the safety of vaccines administered in pregnancy. The consortium developed twenty-six standardised definitions for classifying obstetric and infant adverse events. This systematic review sought to evaluate the current state of adverse event reporting in maternal vaccine trials following the publication of the case definitions by GAIA, and the extent to which these case definitions have been adopted in maternal vaccine safety research., Methods: A comprehensive search of published literature was undertaken to identify maternal vaccine research studies. PubMed, EMBASE, Web of Science, and Cochrane were searched using a combination of MeSH terms and keyword searches to identify observational or interventional studies that examined vaccine safety in pregnant women with a comparator group. A two-reviewer screening process was undertaken, and a narrative synthesis of the results presented., Results: 14,737 titles were identified from database searches, 435 titles were selected as potentially relevant, 256 were excluded, the remaining 116 papers were included. Influenza vaccine was the most studied (25.0%), followed by TDaP (20.7%) and SARS-CoV-2 (12.9%).Ninety-one studies (78.4%) were conducted in high-income settings. Forty-eight (41.4%) utilised electronic health-records. The majority focused on reporting adverse events of special interest (AESI) in pregnancy (65.0%) alone or in addition to reactogenicity (27.6%). The most frequently reported AESI were preterm birth, small for gestational age and hypertensive disorders. Fewer than 10 studies reported use of GAIA definitions. Gestational age assessment was poorly described; of 39 studies reporting stillbirths 30.8% provided no description of the gestational age threshold., Conclusions: Low-income settings remain under-represented in comparative maternal vaccine safety research. There has been poor uptake of GAIA case definitions. A lack of harmonisation and standardisation persists limiting comparability of the generated safety data., Competing Interests: Financial support for this work was provided by the European and Developing Countries Clinical Trials Partnership. Clare Cutland and Flor Muñoz were involved in leading the GAIA definition development. Hannah Davies is involved in the GAIA definition revision process., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
9. Molecular epidemiology of Streptococcus agalactiae in non-pregnant populations: a systematic review.
- Author
-
Founou LL, Khan UB, Medugu N, Pinto TCA, Darboe S, Chendi Z, Founou RC, To KN, Jamrozy D, Karampatsas K, Carr VR, Pepper K, Dangor Z, Ip M, Le Doare K, and Bentley SD
- Subjects
- Pregnancy, Adult, Infant, Newborn, Humans, Female, Molecular Epidemiology, Phylogeny, Databases, Factual, Streptococcus agalactiae genetics, Anti-Bacterial Agents
- Abstract
Streptococcus agalactiae (group B Streptococcus , GBS) has recently emerged as an important pathogen among adults. However, it is overlooked in this population, with all global efforts being directed towards its containment among pregnant women and neonates. This systematic review assessed the molecular epidemiology and compared how the lineages circulating among non-pregnant populations relate to those of pregnant and neonatal populations worldwide. A systematic search was performed across nine databases from 1 January 2000 up to and including 20 September 2021, with no language restrictions. The Joanna Briggs Institute (JBI) Prevalence Critical Appraisal Tool (PCAT) was used to assess the quality of included studies. The global population structure of GBS from the non-pregnant population was analysed using in silico typing and phylogenetic reconstruction tools. Twenty-four articles out of 13 509 retrieved across 9 databases were eligible. Most studies were conducted in the World Health Organization European region (12/24, 50 %), followed by the Western Pacific region (6/24, 25 %) and the Americas region (6/24, 25 %). Serotype V (23%, 2310/10240) and clonal complex (CC) 1 (29 %, 2157/7470) were the most frequent serotype and CC, respectively. The pilus island PI1 : PI2A combination (29 %, 3931/13751) was the most prevalent surface protein gene, while the tetracycline resistance tet M (55 %, 5892/10624) was the leading antibiotic resistance gene. This study highlights that, given the common serotype distribution identified among non-pregnant populations (V, III, Ia, Ib, II and IV), vaccines including these six serotypes will provide broad coverage. The study indicates advanced molecular epidemiology studies, especially in resource-constrained settings for evidence-based decisions. Finally, the study shows that considering all at-risk populations in an inclusive approach is essential to ensure the sustainable containment of GBS.
- Published
- 2023
- Full Text
- View/download PDF
10. Meeting report: Towards better risk stratification, prevention and therapy of invasive GBS disease, ESPID research meeting May 2022.
- Author
-
Snoek L, Karampatsas K, Bijlsma MW, Henneke P, Jauneikaite E, Khan UB, Zadoks RN, and Le Doare K
- Abstract
The European Society of Pediatric Infectious Diseases (ESPID) hosted the third Group B Streptococcus (GBS) Research Session in Athens on 11th May 2022, providing researchers and clinicians from around the world an opportunity to share and discuss recent advances in GBS pathophysiology, molecular and genetic epidemiology and how these new insights can help in improving prevention and control of early- and late-onset GBS disease. The meeting provided a state-of-the-art overview of the existing GBS prevention strategies and their limitations, and an opportunity to share the latest research findings. The first presentation provided an overview of current GBS prevention and treatment strategies. In the second presentation, the genomic and antimicrobial resistance profiles of invasive and colonizing GBS strains were presented. The third presentation explained the association of intrapartum antibiotic prophylaxis (IAP) with the development of late-onset disease (LOD) and the interplay of host innate immunity and GBS. The fourth presentation evaluated the role of genomics in understanding horizontal GBS transmission. The fifth presentation focused on the zoonotic links for certain GBS lineages and the last presentation described the protective role of breastmilk. Talks were followed with interactive discussions and concluded with recommendations on what is needed to further GBS clinical research; these included: (i) the development of better risk stratification methods by combining GBS virulence factors, serological biomarkers and clinical risk factors; (ii) further studies on the interplay of perinatal antimicrobials, disturbances in the development of host immunity and late-onset GBS disease; (iii) routine submission of GBS isolates to reference laboratories to help in detecting potential clusters by using genomic sequencing; (iv) collaboration in animal and human GBS studies to detect and prevent the emergence of new pathogenic sequence types; and (v) harnessing the plethora of immune factors in the breastmilk to develop adjunct therapies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023.)
- Published
- 2023
- Full Text
- View/download PDF
11. Transmission of mpox in educational settings and risk of severe disease in children and adolescents-Let's not make the same mistakes as COVID-19 again.
- Author
-
Karampatsas K, Khalil A, Heath PT, Doare KL, and Ladhani SN
- Subjects
- Humans, Child, Adolescent, Mpox (monkeypox), COVID-19
- Published
- 2023
- Full Text
- View/download PDF
12. Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial.
- Author
-
Calvert A, Amirthalingam G, Andrews N, Basude S, Coleman M, Cuthbertson H, England A, Greening V, Hallis B, Johnstone E, Jones CE, Karampatsas K, Khalil A, Le Doare K, Matheson M, Peregrine E, Snape MD, Vatish M, and Heath PT
- Subjects
- Infant, Infant, Newborn, Pregnancy, Humans, Female, Antibodies, Bacterial, Pertussis Vaccine, Vaccination methods, Immunoglobulin G, Whooping Cough prevention & control
- Abstract
Background: Pertussis vaccination in pregnancy is recommended in many countries to provide protection to young infants. The best timing for this vaccination is uncertain. In the UK, vaccination is recommended between 16 weeks and 32 weeks of gestation. In this trial we aimed to investigate the equivalence of three time periods for pertussis vaccination in pregnancy., Methods: In this open-label, equivalence, randomised controlled trial to investigate equivalence of different time windows for pertussis vaccination in pregnancy, participants were randomly assigned (1:1:1 ratio) to receive a pertussis-containing vaccine (Boostrix-inactivated poliovirus vaccine) in one of three gestational age groups, comprising group 1 (≤23 weeks + 6 days), group 2 (24-27 weeks + 6 days), and group 3 (28-31 weeks + 6 days) using a computer-generated randomisation list. The primary outcome was concentration of pertussis-specific antibodies in the infant born at term at birth. Maternal blood sampling was done before and 2 weeks after vaccination and at delivery, together with a cord sample, and an infant sample was collected at least 4 weeks after primary vaccination. Reactogenicity was assessed for 7 days after vaccination. This trial was registered with ClinicalTrials.gov (NCT03908164)., Findings: Between May 7, 2019, and Feb 13, 2020, of 1010 women assessed for eligibility, 364 women were recruited and 351 received the intervention (120 in group 1, 119 in group 2, and 112 in group 3). Equivalence of time periods was demonstrated for anti-pertussis toxin and anti-pertactin IgG concentrations. The cord blood geometric mean concentrations of anti-filamentous haemagglutinin IgG were higher with increasing gestational age at vaccination, such that for infants in group 1 (≤23 weeks + 6 days), equivalence to group 3 (28-31 weeks + 6 days) was not shown. Reported rates of fever were similar between study groups., Interpretation: Pertussis vaccination at three different time intervals in pregnancy resulted in equivalent concentrations of IgG antibodies in infants against two of the three pertussis antigens assessed. Overall, these findings support recommendations to vaccinate any time between 16 weeks and 32 weeks of gestation., Funding: The Thrasher Research Fund and the National Immunisation Schedule Evaluation Consortium through the National Institute for Health and Care Research policy research programme., Competing Interests: Declaration of interests GA and NA report that the Immunisation and Vaccine Preventable Diseases Division has provided vaccine manufacturers with postmarketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. CEJ has done studies on behalf of the University of Southampton and University Hospital Southampton NHS Foundation Trust funded by vaccine manufacturers, including Novavax, Moderna, Medicago, and Pfizer, but receives no personal funding for these activities. CEJ has served on advisory boards, data safety monitoring boards, or as a consultant for Moderna, MSD, Sanofi, Minervax, and Pfizer. MDS has acted as an investigator on behalf of the University of Oxford for studies funded or supported by vaccine manufacturers including GlaxoSmithKline, Pfizer, MCM vaccines, Novavax, AstraZeneca, and Janssen. MDS received no direct financial benefit for this work. From September, 2022 (after completion of this work), MDS became an employee of Medimmune and Moderna. PTH has conducted studies on behalf of St George's, University of London funded by vaccine manufacturers, including AstraZeneca, Novavax, Moderna, Valneva, Janssen, Minervax, and Pfizer, but receives no personal funding for these activities. All other authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Clinical Risk Factors Associated With Late-Onset Invasive Group B Streptococcal Disease: Systematic Review and Meta-Analyses.
- Author
-
Karampatsas K, Davies H, Mynarek M, Andrews N, Heath PT, and Le Doare K
- Subjects
- Adult, Antibiotic Prophylaxis adverse effects, Female, Humans, Infant, Newborn, Infant, Premature, Infectious Disease Transmission, Vertical prevention & control, Male, Pregnancy, Risk Factors, Streptococcus agalactiae, Young Adult, Infant, Newborn, Diseases etiology, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious epidemiology, Streptococcal Infections prevention & control
- Abstract
Background: Group B streptococcal (GBS) infection remains one of the most significant causes of late-onset sepsis and meningitis (LOGBS) among young infants. However, transmission routes and risk factors for LOGBS are not yet fully understood., Methods: We conducted systematic reviews on clinical risk factors previously reported in the literature (prematurity, low birth weight [<2500 g], antenatal colonization, multiple-gestation pregnancy, maternal age <20 years, male infant sex, intrapartum fever, prolonged rupture of membranes) and meta-analyses to determine pooled estimates of risk., Results: We included 27 articles, reporting 5315 cases. Prematurity (odds ratio [OR] 5.66; 95% confidence interval [CI]: 4.43-7.22), low birth weight (OR 6.73; 95% CI: 4.68-9.67), maternal colonization (2.67; [2.07-3.45]), and multiple-gestation pregnancies (OR 8.01; 95% CI: 5.19-12.38) were associated with an increased risk of LOGBS., Conclusions: Prematurity/low birth weight and maternal colonization are major risk factors for LOGBS. Future GBS vaccine studies should try to establish the optimal time for vaccination during pregnancy to protect preterm infants., Competing Interests: Potential conflicts of interest. K. L. D. is supported by Future Leaders Fellowships by UK Research and Innovation (UKRI) Future Leaders Fellowship (MR/S016570/1). P. T. H. reports research grants to the institution from Pfizer and Minervax outside of the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
14. Invasive Group B Streptococcus Disease With Recurrence and in Multiples: Towards a Better Understanding of GBS Late-Onset Sepsis.
- Author
-
Freudenhammer M, Karampatsas K, Le Doare K, Lander F, Armann J, Acero Moreno D, Boyle M, Buxmann H, Campbell R, Chalker V, Cunney R, Doherty L, Davies E, Efstratiou A, Elling R, Endmann M, Essers J, Hentschel R, Jones CE, Kallsen S, Kapatai G, Krüger M, Ladhani S, Lamagni T, Lindsay D, Meehan M, O'Sullivan CP, Patel D, Reynolds AJ, Roll C, Schulzke S, Smith A, Stein A, von der Wense A, Voss E, Wieg C, Härtel C, Heath PT, and Henneke P
- Subjects
- Age of Onset, Anti-Bacterial Agents therapeutic use, Dysbiosis etiology, Europe epidemiology, Female, Humans, Infant, Newborn, Male, Microbiota, Pregnancy, Pregnancy Complications, Infectious, Recurrence, Retrospective Studies, Risk Factors, Triplets, Twins, Anti-Bacterial Agents adverse effects, Drug-Related Side Effects and Adverse Reactions epidemiology, Dysbiosis epidemiology, Sepsis epidemiology, Streptococcal Infections epidemiology, Streptococcus physiology
- Abstract
Group B Streptococcus (GBS) is a common intestinal colonizer during the neonatal period, but also may cause late-onset sepsis or meningitis in up to 0.5% of otherwise healthy colonized infants after day 3 of life. Transmission routes and risk factors of this late-onset form of invasive GBS disease (iGBS) are not fully understood. Cases of iGBS with recurrence (n=25) and those occurring in parallel in twins/triplets (n=32) from the UK and Ireland (national surveillance study 2014/15) and from Germany and Switzerland (retrospective case collection) were analyzed to unravel shared (in affected multiples) or fixed (in recurrent disease) risk factors for GBS disease. The risk of iGBS among infants from multiple births was high (17%), if one infant had already developed GBS disease. The interval of onset of iGBS between siblings was 4.5 days and in recurrent cases 12.5 days. Disturbances of the individual microbiome, including persistence of infectious foci are suggested e.g. by high usage of perinatal antibiotics in mothers of affected multiples, and by the association of an increased risk of recurrence with a short term of antibiotics [aOR 4.2 (1.3-14.2), P=0.02]. Identical GBS serotypes in both recurrent infections and concurrently infected multiples might indicate a failed microbiome integration of GBS strains that are generally regarded as commensals in healthy infants. The dynamics of recurrent GBS infections or concurrent infections in multiples suggest individual patterns of exposure and fluctuations in host immunity, causing failure of natural niche occupation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Freudenhammer, Karampatsas, Le Doare, Lander, Armann, Acero Moreno, Boyle, Buxmann, Campbell, Chalker, Cunney, Doherty, Davies, Efstratiou, Elling, Endmann, Essers, Hentschel, Jones, Kallsen, Kapatai, Krüger, Ladhani, Lamagni, Lindsay, Meehan, O’Sullivan, Patel, Reynolds, Roll, Schulzke, Smith, Stein, von der Wense, Voss, Wieg, Härtel, Heath and Henneke.)
- Published
- 2021
- Full Text
- View/download PDF
15. Bronchiolitis: an update on management and prophylaxis.
- Author
-
Karampatsas K, Kong J, and Cohen J
- Subjects
- Bronchiolitis prevention & control, Bronchodilator Agents therapeutic use, Cannula, Fluid Therapy methods, Glucocorticoids therapeutic use, Humans, Oxygen Inhalation Therapy methods, Palivizumab administration & dosage, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, State Medicine, United Kingdom, Bronchiolitis therapy, Clinical Protocols
- Abstract
Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in young children less than 2 years of age in the UK. Respiratory syncytial virus is the most common virus associated with bronchiolitis and has the highest disease severity, mortality and cost. Bronchiolitis is generally a self-limiting condition, but can have serious consequences in infants who are very young, premature, or have underlying comorbidities. Management of bronchiolitis in the UK is guided by the National Institute for Health and Care Excellence (2015) guidance. The mainstays of management are largely supportive, consisting of fluid management and respiratory support. Pharmacological interventions including nebulized bronchodilators, steroids and antibiotics generally have limited or no evidence of efficacy and are not advised by National Institute of Health and Care Excellence. Antiviral therapeutics remain in development. As treatments are limited, there have been extensive efforts to develop vaccines, mainly targeting respiratory syncytial virus. At present, the only licensed product is a monoclonal antibody for passive immunisation. Its cost restricts its use to those at highest risk. Vaccines for active immunisation of pregnant women and young infants are also being developed.
- Published
- 2019
- Full Text
- View/download PDF
16. Screening for colonisation with gentamicin-resistant Gram-negative organisms on the neonatal unit: does positive screening predict sepsis?
- Author
-
Walker O, Babb C, Karampatsas K, Richards J, and Kennea N
- Subjects
- Anti-Bacterial Agents pharmacology, Humans, Infant, Newborn, Infection Control methods, Infection Control standards, Predictive Value of Tests, Retrospective Studies, United Kingdom, Drug Resistance, Microbial, Gentamicins pharmacology, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections diagnosis, Gram-Negative Bacterial Infections drug therapy, Mass Screening methods, Mass Screening standards, Neonatal Sepsis diagnosis, Neonatal Sepsis microbiology, Neonatal Sepsis prevention & control
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2019
- Full Text
- View/download PDF
17. Clinical characteristics and complications of rotavirus gastroenteritis in children in east London: A retrospective case-control study.
- Author
-
Karampatsas K, Osborne L, Seah ML, Tong CYW, and Prendergast AJ
- Subjects
- Adolescent, Case-Control Studies, Child, Child, Preschool, Feces virology, Female, Gastroenteritis immunology, Gastroenteritis virology, Hospitalization, Humans, Infant, Infant, Newborn, London, Male, Retrospective Studies, Rotavirus immunology, Rotavirus Infections immunology, Rotavirus Infections virology, Rotavirus Vaccines immunology, Vaccination methods, Gastroenteritis complications, Rotavirus pathogenicity, Rotavirus Infections complications
- Abstract
Background: Rotavirus is the leading cause of acute gastroenteritis in children and is associated with neurological complications such as seizures and encephalopathy. The aim of this study was to investigate the presentation and complications of rotavirus compared to non-rotavirus gastroenteritis in UK children., Methods: This was a retrospective, case-control, hospital-based study conducted at three sites in east London, UK. Cases were children aged 1 month to 16 years diagnosed with acute gastroenteritis between 1 June 2011 and 31 December 2013, in whom stool virology investigations confirmed presence of rotavirus by PCR. They were matched by age, gender and month of presentation to controls with rotavirus-negative gastroenteritis., Results: Data were collected from 116 children (50 cases and 66 controls). Children with rotavirus gastroenteritis tended to present more frequently with metabolic acidosis (pH 7.30 vs 7.37, P = 0.011) and fever (74% versus 46%; P = 0.005) and were more likely to require hospitalisation compared to children with non-rotavirus gastroenteritis (93% versus 73%; P = 0.019). Neurological complications were the most common extra-intestinal manifestations, but did not differ significantly between children with rotavirus-positive gastroenteritis (RPG) and rotavirus-negative gastroenteritis (RNG) (24% versus 15%, respectively; P = 0.24). Encephalopathy occurred only in children with rotavirus infection (n = 3, 6%)., Conclusion: Rotavirus causes longer and more severe disease compared to other viral pathogens. Seizures and milder neurological signs were surprisingly common and associated with multiple pathogens, but encephalopathy occurred only in children with rotavirus gastroenteritis. Rotavirus vaccination may reduce seizures and presentation to hospital, but vaccines against other pathogens causing gastroenteritis are required.
- Published
- 2018
- Full Text
- View/download PDF
18. Rotavirus-associated mild encephalopathy with a reversible splenial lesion (MERS)-case report and review of the literature.
- Author
-
Karampatsas K, Spyridou C, Morrison IR, Tong CY, and Prendergast AJ
- Subjects
- Brain diagnostic imaging, Brain Diseases virology, Central Nervous System Infections diagnosis, Central Nervous System Infections virology, Child, Preschool, Corpus Callosum diagnostic imaging, Diarrhea etiology, Feces virology, Fever etiology, Gastroenteritis virology, Humans, Magnetic Resonance Imaging, Male, RNA, Viral analysis, Radiography, Rotavirus isolation & purification, Brain Diseases diagnosis, Gastroenteritis diagnosis, Rotavirus genetics
- Abstract
Background: Rotavirus is the most common cause of severe gastroenteritis in children under the age of 5 years worldwide. It is well recognised that rotavirus can cause signs and symptoms beyond the gastrointestinal tract, including neurological manifestations such as encephalopathy. Mild encephalopathy with a reversible splenial lesion (MERS) is a clinico-radiological syndrome that has been associated with rotavirus. We report a case of a 4-year-old boy with clinically mild encephalopathy, who had an isolated splenial lesion in the corpus callosum on neuroimaging, and rotavirus RNA detected in faeces. We use this case as an opportunity to review the literature on rotavirus-associated MERS., Case Presentation: A previously healthy 4-year-old boy presented with a 2-day history of vomiting, diarrhoea, and fever, complicated by reduced level of consciousness. Magnetic resonance imaging of the brain showed a marked hyperintensity in the splenium of the corpus callosum on T2 and diffusion-weighted images. Rotavirus genome was detected by polymerase chain reaction in a stool specimen, but not in the cerebrospinal fluid. The genotype was identified as G1P8. His clinical condition improved with gradual resolution of his symptoms. No neurological complications were evident upon discharge and the patient had no recurring symptoms or significant residual defects when followed up 2 months later., Conclusion: MERS is a novel clinic-radiological syndrome first described in Japan. A transient splenial lesion with reduced diffusion that appears as a high signal intensity in diffusion-weighted MRI is the main diagnostic feature. Rotavirus is one of the most common agents associated with MERS, although to our knowledge only one previous case has been reported from Europe. The majority of patients appear to achieve full recovery following rotavirus-associated MERS, irrespective of treatment. This case, together with other published reports, supports the hypothesis that rotavirus-associated MERS is unlikely to be the result of direct viral invasion of the CNS. It has been suggested that MERS may be caused by intra-myelinic axonal oedema or local inflammatory cell infiltration; however, the pathogenesis remains incompletely understood.
- Published
- 2015
- Full Text
- View/download PDF
19. Chronic meningitis with intracranial hypertension and bilateral neuroretinitis following Mycoplasma pneumoniae infection.
- Author
-
Karampatsas K, Patel H, Basheer SN, and Prendergast AJ
- Subjects
- Abducens Nerve Diseases diagnosis, Abducens Nerve Diseases etiology, Child, Headache cerebrospinal fluid, Headache diagnosis, Headache etiology, Headache microbiology, Humans, Inflammation diagnosis, Inflammation etiology, Intracranial Hypertension cerebrospinal fluid, Intracranial Hypertension diagnosis, Male, Meningitis cerebrospinal fluid, Meningitis diagnosis, Meningitis drug therapy, Meningitis etiology, Meningitis, Aseptic cerebrospinal fluid, Meningitis, Aseptic diagnosis, Meningitis, Aseptic drug therapy, Mycoplasma Infections cerebrospinal fluid, Mycoplasma Infections immunology, Mycoplasma Infections microbiology, Papilledema diagnosis, Papilledema etiology, Retinitis diagnosis, Vision Disorders diagnosis, Vision Disorders etiology, Intracranial Hypertension etiology, Meningitis, Aseptic etiology, Mycoplasma Infections complications, Mycoplasma pneumoniae, Retina pathology, Retinitis etiology
- Abstract
A previously well 12-year-old boy presented with a 2-week history of headache, nausea, vomiting and left-sided weakness. He subsequently developed meningism, right abducens nerve palsy, persistent papilloedema and reduced visual acuity in association with a bilateral macular star, consistent with neuroretinitis. Cerebrospinal fluid (CSF) examination indicated chronic meningitis and serological testing confirmed recent Mycoplasma pneumoniae infection, although PCR in CSF was negative. He was treated for aseptic meningitis with ceftriaxone, aciclovir, azithromycin and acetazolamide for intracranial hypertension, with gradual improvement in clinical condition and visual acuity over several weeks. This is the first report of M. pneumoniae chronic meningitis further complicated with bilateral neuroretinitis and intracranial hypertension. Evidence of central nervous system inflammation in the absence of direct infection suggests an immune-mediated pathophysiology. Although the use of macrolides with antibiotic and immunomodulatory activity might be beneficial, it was not possible to ascertain whether it influenced clinical recovery in this case., (2014 BMJ Publishing Group Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.